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Abstract
Purpose The molecular characterization of circulating
tumor cells (CTCs) is critical to identify the key drivers of
cancer metastasis and devising therapeutic approaches,
particularly for inflammatory breast cancer (IBC) which is
usually diagnosed at advance stages and progresses rapidly.
Methods Genomic alterations in tumor tissue samples were
studied using Foundation OneTM. Single CTCs were iso-
lated using CellSearch followed by single-cell isolation by
DEPArrayTM. Samples with 20 or more CTCs were chosen
to isolate single CTCs using the DEPArrayTM.
Results Genomic alterations were studied in primary
tumor or metastatic sites from 32 IBC patients. Genes with
high-frequency mutations were as follows: TP53 (69%),
RB1 (16%), PIK3CA (13%), and also ErbB2 (3%). At least
once during treatment, CTCs were detected in 26 patients
with metastatic IBC, in two patients with locally advanced
IBC, and four patients had no detectable CTCs. Per 7.5 mL
of blood, fifteen patients (47%) had C20 CTCs and six of
them were chosen at random to isolate single CTCs. These
cells were tested for the presence of TP53, RB1, PIK3CA,
and/or ErbB2 mutations previously found in matching tis-
sue biopsies. The isolated CTCs showed the same muta-
tions as primary or metastatic tumor samples. Intra-patient
CTC heterogeneity was found by the presence of different
CTC subclones, with some CTCs harboring different
combinations of mutated and wild-type genes.
Conclusions Our results indicate that CTCs could repre-
sent a non-invasive source of cancer cells from which to
determine genetic markers as the disease progresses and
identify potential therapeutic targets in IBC patients.




CTC Circulating tumor cell
EpCAM Epithelial cell adhesion molecule
ErbB2 or
Her2
v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 2
FFPE Formalin- fixed paraffin embedded
Fs Frameshift





RB1 Retinoblastoma tumor suppressor
TN Triple-negative
TNBC Triple-negative breast cancer
WBC White blood cells
WGA Whole genome amplification
Electronic supplementary material The online version of this
article (doi:10.1007/s10549-017-4176-x) contains supplementary
material, which is available to authorized users.
& Sandra V. Fernandez
Sandra.Fernandez@fccc.edu
& R. Katherine Alpaugh
R.Alpaugh@fccc.edu
1 Fox Chase Cancer Center, Philadelphia, PA 19111, USA
2 Cynvenio Biosystems, Westlake Village, CA, USA
3 Protocol Support Laboratory, Fox Chase Cancer Center,
333 Cottman Ave., Philadelphia, PA 19111, USA
4 Present Address: Robert H Lurie Comprehensive Cancer
Center of Northwestern University, Chicago, IL, USA
123
Breast Cancer Res Treat
DOI 10.1007/s10549-017-4176-x
Introduction
Inflammatory breast cancer (IBC) is a very aggressive type
of advanced breast cancer with a poor prognosis. The
clinical symptoms of IBC involve the rapid onset of
changes in the skin overlaying the breast, including edema,
redness, and swelling, exhibiting a wrinkled, orange peel-
like appearance of the skin known as peau d’orange [1].
This peculiar presentation is associated with the invasion of
aggregates of tumor cells, defined as tumor emboli, into the
dermal lymphatics, where they obstruct the lymph channels
[2, 3]. IBC currently accounts for only 2–6% of all breast
cancer cases in the United States and up to 20% of all
breast cancer cases globally [4–7]. Due to its propensity to
rapidly metastasize, it is responsible for a disproportionate
number (15%) of breast cancer-related deaths [7–9]. IBC is
either stage III or IV; at the time of diagnosis, virtually all
patients have lymph node metastases and one third of the
patients have metastases in distant organs such as the brain,
the bones, and/or the visceral organs [6].
Metastatic disease is the most common cause of cancer-
related death in patients with solid tumors and it is often
associated with the presence of circulating tumor cells
(CTCs) in the peripheral blood of cancer patients [10].
CTCs have been detected in a majority of epithelial can-
cers, including prostate [11], colorectal [12], and breast
cancers [13]. CTCs are tumor cells shed from either the
primary tumor or its metastases and can thus be regarded as
‘‘liquid biopsies’’ of metastasizing cells. Although their
exact composition is unknown, a fraction of these cells is
thought to be viable metastatic precursors capable of ini-
tiating a clonal metastatic lesion [14, 15]. Little is known
about the timing of CTC release from primary tumors, their
functional properties, or their heterogeneity. Intra-tumor
heterogeneity denotes the coexistence of subpopulations of
cancer cells that differ in their genetic, phenotypic, or
behavioral characteristics within a given primary tumor
and between a given primary tumor and its metastasis.
Thus, intra-tumor heterogeneity poses a tremendous chal-
lenge for the characterization of biomarkers and treatments
selection. In this work, we isolated single CTCs from the
blood of IBC patients in order to analyze the presence of
different mutations found in the primary tumor or meta-
static sites and determine the heterogeneity of these cells.
Materials and methods
Patients
Thirty-two patients with inflammatory breast cancer (IBC)
undergoing systemic treatment for their disease were
included in this study. At the time of the first CTC enu-
meration, 29 patients had metastatic IBC (Stage IV) and
three patients had locally advance IBC (Stage III). Clinical
details and treatment timelines for the 32 patients are given
in Supplementary Information. Targeted treatment out-
comes have also been reported elsewhere on patients
D84455 [16] and I77438 [17].
Genomic studies in tumor samples
Formalin-fixed paraffin embedded (FFPE) tumor tissues
(breast, chest wall, lymph node, bone marrow, liver biopsy,
abdominal skin punch, brain biopsy, and/or pleural fluids)
were used for genomic studies. Ten unstained sections
were cut (5–10 lm) and placed on charged slides and
submitted to Foundation Medicine (Cambridge, MA) for
genetic analysis. Briefly, DNA was isolated from the fixed
tumor cells and genomic analysis was performed using
next-generation sequencing (NGS) (Foundation OneTM).
CTCs enumeration from the blood using CellSearch
One tube of 7.5 mL blood from the IBC patients was drawn
and the CellSearchTM System was used for CTC enrich-
ment and enumeration. After running the blood in the
CellSearchTM system for CTC enumeration, the cells were
recovered from the cassettes in order to be used for single
CTC selection using the DEPArrayTM System (Silicon
Biosystems, San Diego, CA). The standard protocol used
for CTC enrichment is described in Supplemental Materi-
als and Methods. Samples containing a minimum of 20
CTCs were selected and prepared for single-cell selection
using the DEPArrayTM.
Isolation of single CTCs using the DEPArrayTM
system
After the CellSearch enrichment, single CTCs were
selected and isolated using the DEPArrayTM (Silicon
Biosystems) as described in Supplemental Materials and
Methods. Individual CTCs or clustered cells that were a-
cytokeratin (PE)-positive, CD45 (APC)-negative, and
DAPI-positive were recovered in several tubes for genomic
analysis. In addition, individual white blood cells (WBC)
classified as CD45 (APC)-positive, CK (PE)-negative, and
DAPI-positive were selected and recovered as single cells
to use as controls in the genomic studies. Selected cells
were stored at -80 C for genomic analyses.
TP53, ErbB2, PIK3CA, and RB1 mutations in CTCs
Whole genome amplification (WGA) was performed using
the Ampli1TM WGA Kit (Silicon Biosystems). The
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Table 1 Mutations in tumor samples and number of CTCs detected during disease progression in triple-negative IBC patients
Patient ID Age at 
diagnosis
Tissue Number of CTCs ( in 7.5 ml blood) and
IBC stage at that point
Survival
time










J73299 34 Liver  
(month 13)
TP53 P190_H193 >*E
















T77549 47 Chest wall 
(month 22)



























R85453 45 Breast    
(month 8)      































T81354 45 Lymph node
(month 19)











NDA NDA NDA 45 months
S80274 61 Chest wall
(month 20)











J64403 52 Skin central upper 
abdomen
(month 43)
























C65525 55 Chest wall 
(month 30)























NDA NDA 36 months
R67904 72 Lymph node
(month 1)
TP53 W146*,



























M67752 61 Skin of right upper back 
medial
(month 27)














E91111 40 Bone marrow
(month 34)
TP53 G245C, 













L95781 44 Chest wall
(month 8)
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Ampli1TM WGA kit uses a polymerase with proofreading
activity with a lower error rate (4.8 9 10-6) than standard
Taq DNA polymerases. Global amplification consisting of
DNA isolation, restriction digestion, adaptor ligation, and
PCR amplification was performed as described in Supple-
mental Materials and methods [18]. To study TP53, ErbB2,
and PIK3CA mutations in CTCs, reverse and forward
primers were used (Supplementary Table 1). The PCR
products were cleaned using the QIAquick PCR purifica-
tion kit and sequenced using the ABI 3130XL capillary
genetic analyzer. As we were unsuccessful in studying RB1
K720* mutation using specific primers as described before
for other genes, this mutation was studied using next-
generation sequencing (NGS) as described in Supplemental
Materials and Methods.
Results
Mutation analysis of tissue samples from metastatic
IBC patients
A total of 32 patients with IBC were included in the study
(Tables 1 and 2). All the patients were females save one
male (B87480, Table 1), and all of them were at an
advanced clinical stage at time of diagnosis (stage III or
IV). Their median age at diagnosis was 48 years with a
range of 32–72 years old. From the 32 patients, 20 patients
(62.5%) had triple-negative (ER-negative, PgR-negative,
and Her2-negative) IBC (Table 1); five patients (15.6%)
had ER-positive Her2-negative IBC; three patients (9.4%)
had ER-negative Her2-positive IBC; and four patients
(12.5%) had ER-positive Her2-positive IBC at time of
diagnosis (Table 2).
The genomic alterations in the primary tumor or meta-
static sites were determined using the NGS-based cancer
gene test, Foundation OneTM (Tables 1 and 2). IBC
patients showed mutations in the following: TP53 (22/32;
69%), RB1 (5/32; 16%), PIK3CA (4/32; 13%), BRCA1 (3/
32; 9%), BRCA2 (3/32; 9%), and Notch1 (3/32; 9%). Other
mutated genes were ErbB2 (or Her2; 3%), ATM, Kras,
ESR1, EGFR, and PAX5. Also IBC tumor samples showed
amplifications in the following: MYC (8/32; 25%),
CCND1 (7/32; 22%), ErbB2 (5/32; 16%), MCL1 (6/32;
19%), and FGFR1 (3/32; 9%). Interestingly, patient
D66122, who was found to have a triple-negative disease
by the analysis of her first biopsy, a second chest wall
biopsy in month 26 showed amplification of the ErbB2
gene. Based on these results, this patient was subsequently
treated with Herceptin (Table 1 and Supplementary
Information).
Circulating tumor cells (CTCs) enumeration
The number of CTCs present in 7.5 mL of blood was
determined at different points during the patients’ treat-
ments using the CellSearchTM system. From the 32 IBC
patients, CTCs were detected in 28 patients (C5 CTCs/
7.5 mL blood in 24 patients;\5 CTCs/7.5 mL blood in
four patients) at least once during treatment, while four
patients had no detectable CTCs at any point during
treatment (Tables 1 and 2). CTCs were detected in 26
patients with metastatic IBC and two patients with locally
advance IBC. From 20 patients with triple-negative IBC,
Table 1 continued




















TP53 Q104  fs*19 ERBB2












Patient ID Age at 
diagnosis
Tissue Number of CTCs ( in 7.5 ml blood) and
IBC stage at that point
Survival
time
Mutations and gene amplifications in tumor samples are shown. Time of tissue collection (t = 0; time of diagnosis) is indicated in each case. The
survival time since IBC diagnostic is indicated. Several blood samples were run in order to determine the number of CTCs along the patient’s
treatment; in the table, only the highest numbers of CTCs during each 10 month period are indicated (in Supplementary Information, all the
points are shown). Also, the disease stage at the time of CTC enumeration is indicated
In some patients, CTCs were present as clusters; presence of CTCs clusters are indicated as (?). Baseline: CTCs number before neoadjuvant
treatment; NDA no data available because the patient was treated at another institution; ND not-done
The time when patients came to Fox Chase Cancer Center for treatment recommendations and/or blood samples draw for CTC enumeration are
indicated as ()
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16 patients had C5 CTCs/7.5 mL blood, and four patients
had 0–4 CTCs/7.5 mL blood. Patients with triple-negative
IBC had significantly worse overall survival compared to
those with ER-positive Her2-positive IBC (p = 0.011),
ER-positive Her2-negative IBC (p = 0.001), and ER-neg-
ative Her2-positive IBC (p = 0.027) (Fig. 1). Patients in
the ER-positive Her2-negative group had the longest
median survival (ER-positive Her2-negative = 76 months
(95% CI 39–101), Triple-Negative = 31.5 months (95%
CI 20–38), ER-negative Her2-positive = 39 months (95%
CI 23–59.), ER-positive Her2-positive = 49.5 months
(95% CI 21-undet.) (Figure 1). In the ER-positive Her2-
positive group at the time of diagnosis (Table 2), patient
K76386 developed a ER-positive (weak) Her2-negative
component in month 9; and a tumor biopsy performed from
patient B62630 in month 49 showed that the tumor was
ER-positive Her2-negative (Supplementary Information).
CTCs were detected in 26 patients with metastatic IBC
(Stage IV) and in two patients with locally advance IBC
(Stage III) at least once during treatments (Tables 1 and 2).
CTCs were not detected in patient B87480 with triple-
negative IBC (Table 1) nor in patients S71769, I77438, and
J70105 with Her2-positive IBC (Table 2).
In order to successfully isolate single CTC using the
DEPArray, samples from the CellSearch that contain at
least 20 CTCs were used. Per 7.5 mL of blood from the 32
Table 2 Mutations in tumor samples and number of CTCs detected during disease progression in ER-positive Her2-negative, ER-negative Her2-




Age ER PgR Her2 
*
Tissue Number of CTCs / 7.5 ml blood
(IBC stage at that point)
Survival
time















































M85099 44 pos pos neg Pleural fluid
(month 29)
















A89555 44 pos neg neg Right breast
(month 2)










NDA NDA 101 months







































NDA NDA NDA 59 months





































NDA NDA NDA NDA More than 80 
months
-Alive-
K76386 56 pos neg pos Chest wall 















B62630 37 pos pos pos Chest wall     
(month 49)
TP53 S215G CCNE1 ND
(III)












Mutations and amplifications in tumor samples are shown. The age of the patients, the ER/PgR/Her2 status at diagnosis, and survival time since
IBC diagnosis are indicated
The number of CTCs present in 7.5 mL of blood was determined using the CellSearch system
Blood samples were run in order to determine the number of CTCs during the disease progression; only the highest numbers of CTCs, every
10-month period since time of start of treatment, are showed
NDA no data available because the patient was treated in another institution, ND non-done, ? presence of clusters
Baseline number of CTCs before treatment
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IBC patients, fifteen (47%) patients had C20 CTCs, two
(6%) patients had 10–20 CTCs, five patients (16%) had
between 5 and 10 CTC, and six patients (19%) had 1–5
CTCs. Of the 20 patients with triple-negative IBC, CTCs
were detected in 19 of them at some point during the course
of their disease, and 11 of these patients (55%) had more
than 20 CTCs per 7.5 mL of blood (Table 1). CTCs were
detected in all five patients with ER-positive Her2-negative
IBC at least once during their treatment and two of these
patients had more than 20 CTCs per 7.5 mL of blood
(Table 2). Of the seven patients with Her2- positive IBC,
three patients did not show any CTCs (although CTCs were
enumerated only once in them), and two patients had more
than 20 CTCs (Table 2). The two ER-positive Her2-posi-
tive IBC patients with a high number of CTCs were ini-
tially responsive to Herceptin therapy but during disease
progression they failed to respond to the treatment
(K76386 and B62630; Table 2).
Mutations in single circulating tumor cell (CTC)
From the fifteen patients that had C20 CTCs, six were
chosen at random in order to isolate single CTCs using the
DEPArrayTM (Table 3). Among these patients, all but
patient B62630 had triple-negative IBC at diagnosis but,
developed a Her2-negative component during disease
progression as it was previously mentioned (Supplemen-
tary Information). For molecular characterization of single
CTCs, cells were recovered from the CellSearch cassettes
after enumeration as it was described in Supplementary
Materials and Methods, washed and loaded in the
DEPArray cassettes for single-cell isolation. The DEPAr-
rayTM system (Silicon Biosystems, San Diego, CA) is an
automated platform that uses dielectrophoresis and a high-
quality image-based cell selection system that allows for
the identification and recovery of individual cells from
heterogeneous samples [18]. CTCs that were discrete sin-
gle cells were seen in the blood of three patients (J73299,
R85453 and T77549), whereas the remaining three patients
(B62630, L67504, and D84455) had both individual single
CTCs and clusters of associated CTCs (Table 3). Usually,
CTCs clusters were composed by five to 14 associated cells
(Fig. 2). Samples containing single CTCs, pooled single
CTCs, and/or CTCs clusters were selected and recovered
using DEPArrayTM, and the samples were tested for the
presence of mutations previously revealed in tumor sam-
ples from the same patient. WGA was performed on the
isolated CTCs and regions of TP53, ErbB2, and PIK3CA
shown to be mutated in matching tumor tissue were
amplified and sequenced using Sanger’s method. In five of
the six IBC patients where TP53 was mutated in the tumor
tissues, the isolated CTCs showed the same TP53 muta-
tions (Table 3). However, a TP53 S215G mutation was
present in a chest wall biopsy in patient B62630, which was
not observed in either the isolated CTCs or in tumor cells
collected from pleural effusion (Table 2, pleural effusion
Fig. 1 Survival curves
according to ER (estrogen
receptor) and Her2 (ErbB2)
status. Overall survival in the
triple-negative group was lower
than the other groups (TN vs
ER- Her2?, p = 0.011; TN vs
ER? Her2?, p = 0.001; TN vs
ER? Her2-, p = 0.027).
Patients from the ER? Her2-
group had the longest median
survival (76 months, 95% CI
39–101). In the
ER? Her2? group, one patient
was still alive and shown as
censored (?) at the end of the
curve
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from month 50). The TP53 S215G mutation is a missense
mutation in exon 6 (Table 3). The other patients, J73299,
R85453, L67504, and D84455, had TP53 mutations that
produced a premature stop codon in the protein (Table 3).
The liver biopsy of patient J73299 showed a mutation in
TP53 exon 6, TP53 P190_H193[ *E; this mutation was
also found in CTCs isolated from the patient’s blood
(Table 3). Two patients (R85453 and L67504) had a TP53
mutation in exon 4, TP53 R110 fs*13 (Table 3). In patient
L67504, a C deletion (nucleotide 328, delC) was detected
in the chest wall biopsy and the same mutation was found
in the CTCs (Table 3). Patient R85453 showed a G dele-
tion (nucleotide 329, delG) in p53 exon 4 in a breast biopsy
sample (Table 1); while this mutation was also found in
one CTC isolated from the patient, a second CTC revealed
a C deletion (nucleotide 328, delC) that was not previously
detected in the tissue biopsy (Table 3). The chest wall
biopsy of patient D84455 showed a TP53 C229 fs*10
mutation that was also found in three of five single CTCs
analyzed and in one CTC cluster isolated from the patient’s
blood; one single CTC showed the TP53 wild-type allele
and one CTC provided no data as we were unable to suc-
cessfully amplify the region of interest (Table 3). In
Table 4, the deleterious mutations in TP53 are shown.
The RB1 gene was mutated at high frequency in IBC
patients; CTCs isolated from patients T77549 and L67504
were chosen to further study RB1 mutations in single CTCs
(Table 3). RB1 splice mutation 607 ? 1 G[C was
detected in the chest wall biopsy from T77549 and this
mutation was detected in one single CTC and in one pool
of 6 CTCs isolated from the blood of that patient (Table 3).
A second pooled cell sample containing 4 CTCs harbored
RB1 wild type. The RB1 607 ? 1 G[C denotes the G to
C substitution at nucleotide ?1 of the intron (between
exons 6 and 7) in the coding DNA positioned between
nucleotide 607 and 608, resulting in low expression or
partial inactivation of the RB1 protein. Patient L67504
showed a RB1 K720* mutation in her chest wall (Table 1);
the RB1 K720* mutation was also found in two of five
single CTCs and a cluster containing three CTCs that were
isolated from the blood (Table 3). The RB1 K720* muta-
tion is a nonsense variant, a substitution that produces an
Table 3 Mutation analyses in single, pooled, and/or CTCs clusters
Paent
ID #
Mutaons in ssue 
samples
CTCs (single, pools or clusters) WBC control
B62630 TP53 S215G
(chest wall)
5 single CTCs:  
• 5 CTCs: TP53 w. t.
1 cluster of CTCs:  TP53 w. t. 
5 single WBCs: 
• 5 WBCs: TP53 w. t.
J73299 TP53 P190_H193>*E
(liver)
2 single CTCs: 
• 2 CTCs: TP53 P190_H193>*E
4 single WBCs: 
• 4 WBCs: TP53 w. t.
R85453 TP53 R110 delG fs*13
(breast biopsy)
6 single CTCs: 
• 1 CTCs: TP53 R110 delG fs*13
• 1 CTC:  TP53  R110 delC fs*13
• 4 CTCs: TP53 w. t.
1 pool of 14 CTCs:  TP53 R110 delC fs*13
4 single WBCs: 
• 4 WBCs: TP53 w. t. 
T77549 RB1 607+1 G>C
(chest wall)
1 single CTC:
• RB1 607+1 G>C 
2 pools of CTCs:
• 1 pool of 6 CTCs: RB1 607+1 G>C 
• 1 pool of 4 CTCs: RB1 w.t.
1 single WBC: 
• RB1 w. t.  
1 pool of 5 WBCs:
• RB1 w. t. 
L67504




5 single CTCs:  
• 2 CTCs: TP53 R110 delC fs*13; RB1 K720* 
• 2 CTCs: TP53 w. t.; RB1 w.t.
• 1 CTC: TP53 R110 delC fs*13; RB1 w.t.
1 cluster of 3 CTCs:
• TP53 R110 delC fs*13;  RB1 K720* 
3 single WBCs:
•2 WBCs: TP53 w. t.; RB1 w.t.;
BRCA2 w.t.








5 single CTCs: 
• 2 CTCs: TP53 C229 fs*10; ERBB2 exon 12  S310F; ERBB2 exon 24 V777L; PIK3CA K111E 
• 1 CTC: TP53 w.t.; ERBB2 S310F; ERBB2 V777L; PIK3CA w.t.
• 1 CTC: : TP53 C229 fs*10; ERBB2 exon 12 n.d.; ERBB2 exon 24 w.t.; PIK3CA n.d.
• 1 CTC: : TP53 n.d.; ERBB2 exon 12 S310F;  ERBB2 exon 24 w.t.; PIK3CA n.d.
1 cluster of CTCs: TP53 C229 fs*10; ERBB2 S310F; ERBB2 V777L; PIK3CA K111E
4 single WBC:
• 4 WBCs: TP53 w.t.; ERBB2 w.t.; 
PIK3CA w.t.
Single CTCs, pooled single CTCs, and/or CTCs clusters were recovered using DEPArray. Mutations in TP53, ErbB2, PIK3CA, and RB1 found
in tumor tissue samples were detected in the CTCs
Intra-patient heterogeneous CTCs populations were found; w.t. wild type; n.d. non-done (because not enough amplified DNA)
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immediate stop codon. This patient also showed a BRCA2
p.A1326 fs*4 mutation in her chest wall biopsy (Table 1);
the BRCA2 p.A1326 fs*4 mutation was detected in one of
three white blood cells (WBC) used as controls, suggesting
that the BRCA2 mutation is a germline mutation. This
mutation was not investigated in the isolated CTCs. In both
patients that had RB1 mutations, some CTCs showed the
RB1 mutations and others showed the wild-type RB1 allele
(Table 3).
The chest wall biopsy from patient D84455 had two
mutations in ErbB2: S310F in exon 12, and V777L in exon
24; this patient also had a mutation in PIK3CA K111E, in
addition to the TP53 C229 fs*10 mutation previously
described (Table 3). These mutations were studied in five
single CTCs and one CTC cluster. Two single CTCs and
the cluster showed all the mutations detected in the chest
wall biopsy; another single CTC only showed the ErbB2
mutations (ErbB2 S310F and ErbB2 V777L) and wild-type
alleles of TP53 and PIK3CA. Another single CTC showed
the ErbB2 mutation on exon 12 (ErbB2 S310F), the wild-
type allele on exon 24, but the amplified DNA was not
enough to study TP53 and PIK3CA in this cell (Table 3).
The remaining single CTC showed the mutated TP53
(TP53 C229 fs*10) and ErbB2 exon 24 wild type. Results
indicated that patients D84455 and L67504, in which
mutations in more than one gene were studied, had a
heterogeneous population of CTCs (Table 3).
Discussion
Genomic alterations were studied in primary and/or meta-
static tumor samples from 32 patients with IBC. Most of the
patients had triple-negative IBC and had mutations in TP53,
RB1, and/or PIK3CA. CTCs were detected in 28 of the 32
IBC patients included in this study. Single CTCs isolated
from the blood of six of these patients showed the same
mutations as primary or metastatic tumor samples indicat-
ing that CTCs can potentially be used to monitor disease
progression. Our results show that mutations in driver genes
found in the primary tumor and/or the metastasis in IBC
patients could be identified in the CTCs. Furthermore, the
mutational analysis of the TP53, RB1, PIK3CA, and ErbB2
genes revealed heterogeneity of CTCs.
Deleterious TP53 mutations found in tissue samples or
pleural effusions of IBC patients were also present in CTCs
isolated from their blood. In the majority of the IBC
patients with TP53 mutations, these mutations resulted in a
Fig. 2 Single and clusters of CTCs from a patient with triple-
negative metastatic IBC visualized in the DEPArrayTM. Tumor cells
were defined as presence of a clear DAPI-stained nucleus, CK-PE-
positive cytoplasm, and CD-45-APC negativity. Separate images for
PE (green), DAPI (magenta), APC (blue) fluorescence, bright field
channels, and merged CK-PE/DAPI and CD45-APC/DAPI images
are shown. Single CTCs and a cluster of CTCs from a metastatic
triple-negative IBC patient (D84455) are shown; also, four white
blood cells (WBC) collected to use as controls for the molecular
studies are shown
Breast Cancer Res Treat
123
non-functional protein. A non-functional TP53 has been
shown to offer survival advantages to the cancer cells by
facilitating growth, anoikis resistance, and the emergence
of a potentially more aggressive malignancy [19]. TP53
mutations are exceptionally frequent in cancer and are
among the key driving factors in triple-negative breast
cancer (TNBC) [20]. Furthermore, TP53 mutations are
more frequent in inflammatory breast cancer (50%) than in
non-inflammatory breast cancer (20–30%) [21, 22]. TP53
mutations have been shown to predict a poor response to
anthracycline-based neoadjuvant chemotherapy [23–25];
others suggested that TP53 mutations confer sensitivity to
taxane [26, 27]. A recent study suggested that patients with
TP53 mutations are more likely to respond to anthracy-
cline/cyclophosphamide-based neoadjuvant chemotherapy
[28]. Several clinical trials are ongoing to study TP53-
mutated breast cancer sensitivity to different chemothera-
peutic agents. Other clinical trials are targeted towards
either expression of the wild-type TP53, suppressing
expression of mutated TP53, or strategies that involve
targeting of the cell cycle regulator Wee-1 tyrosine kinase
inhibitors (clinicaltrials.gov).
RB1 mutations were found in only the triple-negative
IBC patients from this study, and all of these mutations
render a premature stop codon and a non-functional RB1
protein. RB1 mutations were also detected in the CTCs.
RB1 mediates cell cycle control and is frequently inacti-
vated in human TNBC [29–31]. There are targeted inhi-
bitors that are currently in advanced clinical testing for
tumors harboring RB1 and PIK3CA mutations [32, 33].
One triple-negative IBC patient (D84455) with a dele-
terious TP53 mutation also showed two ErbB2 mutations
(V777L and S310F). Both mutations activate ErbB2 by
either affecting its auto-phosphorylation or phosphoryla-
tion of downstream substrates in breast cancer cells
[34–36]. Initially, this patient had ER? Her2? invasive
ductal carcinoma (IDC) in the left breast that was treated
with standard local therapies over 2 years and this patient
subsequently developed triple-negative IBC in the same
breast [16] (Supplementary Information). This suggests
that the ErbB2 pathway could be the driver of this patient’s
disease even in the absence of ErbB2 amplification. Fur-
thermore, this patient had a PIK3CA K111E mutation
which is also an activating mutation [37, 38]. All the
mutations detected in the chest wall biopsy of patient
D84455 were detected in the CTCs isolated from their
blood. A heterogeneous population of CTCs were found in
this patient with some CTCs showing the mutated genes
Table 4 TP53 deleterious mutations in IBC tumor and CTCs
TP53 mutations found in CTCs
Patient ID
#
Exon Mutation Sequence Effect
J73299 6
P190_H193>*E aa: 187      






R110 delG fs*13 aa: 109 
TTC CGT   CTG GGC TTC T TG CAT TCT G GG ACA GCC AAG TCT G TG A




aa: 109             
TTC  CGT  C TG G GC T TC T TG C AT T CT G GG A CA G CC A AG T CT G TG A




R110 delC fs*13 aa: 109 
TTC  CGT  C TG G GC T TC T TG C AT T CT G GG A CA G CC A AG T CT G TG A
nt: 325                                                                                                                        Stop codon
Premature 
stop codon
D84455 7 C229 fs*10 aa: 225    




The TP53 P190_H193[*E mutation is a 12 base pair (bp) deletion that causes the loss of amino acids at position 190 (P) to 193 (H), and the
insertion of 6 nucleotides (TAA GAG) that produce a premature stop codon in the protein
TP53 R110 fs*13 is a frame shift deleterious mutation that causes a stop codon at position 122 (nucleotide 366) of TP53 with the loss of the
protein
The TP53 C229 fs*10 is a mutation in exon 7 of TP53 consisting in a 2 bp. deletion
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and others showing different combinations of the mutated
and wild-type genes.
It has been successfully demonstrated by single-cell
sequencing that many breast cancers are composed of
multiple distinct subclones [39]. Intra-patient cellular
heterogeneity is widely reported in epithelial malignancies
and it is expected that CTCs will also be heterogeneous
[40–42]. Our results are consistent with previous findings
which showed a heterogeneous pattern of genomic muta-
tions on single CTCs obtained from breast, esophageal, and
colorectal cancer patients [42–44].
Our results demonstrate that we were able to select
uncontaminated CTCs by combining the CellSearch and
DEPArrayTM systems. However, one disadvantage of the
DEPArrayTM is that there is approximately 40% cell-loss,
although the DEPArray cartridge is manually loaded with
14 lL of sample, only 9.26 lL of sample is injected into
the micro-chamber of the cartridge. We found that in order
to successfully isolate single CTC, samples with 20 CTCs
or more should be used to load in the DEPArray cassette. In
order to perform molecular analysis of CTCs in samples
with less than 20 CTCs per 7.5 mL blood, multiple samples
from the same patient could potentially be combined after
the CellSearch and loaded in the DEPArray cassette.
However, despite the promise of CTCs as multifunctional
biomarkers, there are still numerous challenges that hinder
their incorporation into standard clinical practice. Some
patients showed little to no CTCs even though their disease
was progressing. This is the case for most of the patients with
Her2-positive IBC, with the exception of patients K76386
and B62630 who developed a Her2-negative component
during their disease progression; both had high number of
CTCs. Patients with Her2-positive IBC were treated with
Herceptin for a long period of time, so this could explain why
CTCs were not present in their blood due to the high speci-
ficity of these antibodies. In addition, the CellSearchTM,
relies on the detection of the surface epithelial cell adhesion
molecule EpCAM, and the existence of an EpCAM-negative
subpopulation of CTCs had been described in patients with
Her2-positive metastatic breast cancer [45]; therefore, it will
be interesting to combine different pre-enrichment strategies
with the DEPArray in order to study these cells, especially in
Her2-positive IBC.
It has been shown that elevated CTC at baseline or at
any time through the course of metastatic breast cancer is
associated with worse prognosis; patients with C5 CTCs/
7.5 mL blood had a shorter overall survival compared with
the patients with\5CTCs/7.5 mL blood, and elevated
CTCs while on treatment ultimately are predictive of an
ineffective therapy [13, 46]. Our data showed that the
distribution of CTCs in the patients with serial blood draws
during the treatments varied; many patients were initially
CTCs negative but converted to positive and vice versa.
Based on our results, single time-point measurements of
CTCs seem to be inadequate, and could result in incorrect
microscopic disease staging. Collecting sequential blood
samples for real-time monitoring of the efficacy of sys-
temic therapies would offer new possibilities in evaluating
targeted therapies based on genomic profiling of CTCs and
improving the clinical management of patients with IBC.
In order to implement these studies in future clinical
practice, we are developing protocols in order to study
mutations in single, pools, and clusters of CTCs using NGS
and a panel of 15 genes frequently mutated in IBC.
This work demonstrates that the isolation and pooling of
CTCs from IBC patients can be used for genomic analysis,
both to initially identify targetable mutations where solid
tumor samples are unavailable and to be used as a bio-
marker to reveal which cell populations are affected by the
current or previous therapy. Our results suggest that CTCs
represent the entire spectrum of the primary tumor and
distal metastases for patients with IBC. Furthermore, our
studies showed the presence of different CTCs subclones in
the peripheral blood of IBC patients.
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